NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that data demonstrating SL-401 efficacy in multiple myeloma (MM) preclinical models will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2014 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
